Skip to content

Celcuity CELC Investment Proceeds

Investment Proceeds at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10M
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$83.8M+29.3%
CG Oncology logo
CG OncologyCGON
$252.85M+26.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$302.89M-1.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$133.86M+0.8%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's investment proceeds?
Celcuity (CELC) reported investment proceeds of $50M in Q1 2026.
How has Celcuity's investment proceeds changed year-over-year?
Celcuity's investment proceeds decreased by 25.2% year-over-year, from $66.81M to $50M.
What is the long-term trend for Celcuity's investment proceeds?
Over 2 years (2023 to 2025), Celcuity's investment proceeds has grown at a 3.6% compound annual growth rate (CAGR), from $309.61M to $332.51M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.